Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary

International Journal of Gynecological Cancer

Volumn 20, Issue 5, 2010, Pages 794-797

  Tsuda, Hiroshi ^a,b   Ito, Kiyoshi ^c   Yaegashi, Nobuo ^c   Hirasawa, Akira ^a   Sudo, Tamotsu ^d   Kita, Tsunekazu ^e   Terai, Yoshito ^f   Kigawa, Junzo ^g   Sugiyama, Toru ^h   Aoki, Daisuke ^a  

^a KEIO UNIVERSITY   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d HYOGO CANCER CENTER   (Japan)

^e NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^f OSAKA MEDICAL COLLEGE   (Japan)

^g TOTTORI UNIVERSITY   (Japan)

^h IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

ABC transporter; Clear cell adenocarcinoma; Prognosis

Indexed keywords

ADENOSINE TRIPHOSPHATE BINDING CASSETTE SUPERFAMILY F2; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL; PROTEIN; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CYTOPLASM; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT RESPONSE;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; OVARIAN NEOPLASMS; PLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 77956821073     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a835fc     Document Type: Article

References (11)

1. Goff BA, Sainz de la Cuesta R, Muntz HG, et al. Clear cell carcinoma of the ovary: A distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage 3 disease. Gynecol Oncol. 1996;60:412Y417.
2. Behbakht K, Randall TC, Benjamin I, et al. Clinical characteristics of clear cell carcinoma of the ovary. Gynecol Oncol. 1998;70:255Y258.
3. Takano M, Kikuchi Y, Yaegashi N, et al. Clear cell carcinoma of the ovary: A retrospective multicentre experience of 254 patients with complete surgical staging. Br J Cancer. 2006;94:1369Y1374.
4. Takano M, Kikuchi Y, Yaegashi N, et al. Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. Oncol Rep. 2006;16:1301Y1306.
5. Tsuda H, Ito YM, Ohashi Y, et al. Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses. Clin Cancer Res. 2005;11:6880Y6888.
6. Nishimura S, Tsuda H, Ito K, et al. Differential expression of ABCF2 protein among different histologic types of epithelial ovarian cancer and in clear cell adenocarcinomas of different organs. Hum Pathol. 2007;38:134Y139.
7. Vazquez de Aldana CR, Marton MJ, Hinnebusch AG. GCN20, a novel ATP binding cassette protein, and GCN1 reside in a complex that mediates activation of the elF-2> kinase GCN2 in amino acidYstarved cells. EMBO J. 1995;14: 3184Y3199.
8. Allikmets R, Gerrard B, Hutchinson A, et al. Characterization of the human ABC superfamily: Isolation and mapping of 21 new genes using the expressed sequence tags database. Hum Mol Genet. 1996;5:1649Y1655.
9. Kerr ID. Sequence analysis of twin ATP binding cassette proteins involved in translational control, antibiotic resistance, and ribonuclease L inhibition. Biochem Biophys Res Commun. 2004;315:166Y173.
10. Yasui K, Mihara S, Zhao C, et al. Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res. 2004;64:1403Y1410.
11. Ogawa Y, Tsuda H, Hai E, et al. Clinical role of ABCF2 expression in breast cancer. Anticancer Res. 2006;26: 1809Y1814.